<unk>  is a {{{drugClass}}} that is FDA approved for the treatment of clinically significant hypervolemic and euvolemic hyponatremia, (serum sodium <125 mEq/L or less marked hyponatremia that is symptomatic and has resisted correction with fluid restriction), including patients with heart failure and Syndrome of Inappropriate Antidiuretic Hormone (SIADH).. There is a Black Box Warning for this drug as shown here.  Common adverse reactions include hyperglycemia, constipation, increased thirst, nausea, xerostomia, asthenia, dizziness, polyuria, dehydration.
Tolvaptan
Conivaptan
Bumetanide 
Amiloride
Paricalcitol 
Mitobronitol
Tacalcitol
Mannitol